Posted inMarket
Scott Bizily Sells Shares of 4D Molecular Therapeutics
Discover the latest insider trading details as Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, executes a recent stock sale.
Posted inMarket
Spyre Therapeutics CEO Cameron Turtle Sells 1.3 Million Dollars in Stock
Spyre Therapeutics CEO Cameron Turtle recently sold 1.3 million dollars in company shares. Discover the details of this notable insider transaction.
Posted inMarket
PYC Therapeutics Q3 2026 Earnings Beat Expectations Driven by Strong Trial Data
Discover how PYC Therapeutics surpassed Q3 2026 earnings per share estimates, fueled by positive clinical trial results and an upgraded outlook.
Posted inMarket
Fulgent Genetics CSO Hanlin Gao Offloads Stock Valued at Over 32000 Dollars
Discover the recent insider trading activity as Fulgent Genetics Chief Scientific Officer Hanlin Gao sells company stock worth over 32000 dollars.
Posted inMarket
MPM BioVentures Executes Significant Share Sale in Entrada Therapeutics
Discover the latest insider trading activity as major shareholder MPM BioVentures sells over six hundred thousand dollars in Entrada Therapeutics stock.
Posted inMarket
BTIG Raises Climb Bio Stock Price Target to $32 Following Phase 1 Data
BTIG has increased its price target for Climb Bio stock to $32 following promising phase 1 clinical trial data results.
Posted inMarket
Vertex Pharmaceuticals Secures Top Spot on Citi Biotech Picks
Vertex Pharmaceuticals claims the top position on Citi's biotech stock picks following the successful completion of the Crinetics acquisition.
Posted inMarket
Baird Increases Climb Bio Stock Price Target Following Trial Data
Financial firm Baird has raised its price target for Climb Bio stock to $25 following recent clinical trial data updates.
